Matches in Nanopublications for { ?s <http://www.w3.org/2000/01/rdf-schema#label> ?o ?g. }
- association label "The off label antipsychotic treatments we considered were sulpiride, olanzapine, pimozide, quetiapine, risperidone, haloperidol, tiapride, chlorpromazine, and aripiprazole. We estimated the effect of antipsychotics as a group, and also estimated effects of certain individual antipsychotic chorea drugs (i.e. olanzapine, risperidone, and tiapride) commonly taken in our cohort." assertion.
- context label "Adults" assertion.
- association label "The off label antipsychotic treatments we considered were sulpiride, olanzapine, pimozide, quetiapine, risperidone, haloperidol, tiapride, chlorpromazine, and aripiprazole. We estimated the effect of antipsychotics as a group, and also estimated effects of certain individual antipsychotic chorea drugs (i.e. olanzapine, risperidone, and tiapride) commonly taken in our cohort." assertion.
- context label "Adults" assertion.
- association label "The off label antipsychotic treatments we considered were sulpiride, olanzapine, pimozide, quetiapine, risperidone, haloperidol, tiapride, chlorpromazine, and aripiprazole. We estimated the effect of antipsychotics as a group, and also estimated effects of certain individual antipsychotic chorea drugs (i.e. olanzapine, risperidone, and tiapride) commonly taken in our cohort." assertion.
- DB13025 label "Tiapride" assertion.
- context label "Adults" assertion.
- association label "The off label antipsychotic treatments we considered were sulpiride, olanzapine, pimozide, quetiapine, risperidone, haloperidol, tiapride, chlorpromazine, and aripiprazole. We estimated the effect of antipsychotics as a group, and also estimated effects of certain individual antipsychotic chorea drugs (i.e. olanzapine, risperidone, and tiapride) commonly taken in our cohort." assertion.
- DB00477 label "Chlorpromazine" assertion.
- context label "Adults" assertion.
- association label "The off label antipsychotic treatments we considered were sulpiride, olanzapine, pimozide, quetiapine, risperidone, haloperidol, tiapride, chlorpromazine, and aripiprazole. We estimated the effect of antipsychotics as a group, and also estimated effects of certain individual antipsychotic chorea drugs (i.e. olanzapine, risperidone, and tiapride) commonly taken in our cohort." assertion.
- context label "Adults" assertion.
- association label "Guidelines for the pharmacological treatment of chronic insomnia in adults recognize that trazodone and other off-label medications are commonly prescribed despite poor evidence." assertion.
- context label "Children and adolescents (6-17 years)" assertion.
- association label "Paliperidone is FDA-approved for schizophrenia aged 12-17. However, the pharmacologic portfolio, extrapolation from adult studies, and the long track record of the parent drug, risperidone in child/adolescent psychiatric (CAP) population might expand its therapeutic potential. An 8-week open-label study [9] examined paliperidone monotherapy for acute mania, mixed, or hypomanic episode in pediatric patients (n = 15, 6–17 years of age) with bipolar spectrum disorders. At the end of follow-up period, 11 subjects (73%) completed the study; treatment with paliperidone was associated with a 60% response rate (50% decrease in the Young Mania Rating Scale) and 40% remission (YMRS <12)" assertion.
- context label "Children and adolescents (mean age 13.4 years)" assertion.
- association label "Fernandez-Mayoralas et al. [12] have conducted a prospective 16-week open-label study of paliperidone in 18 patients (mean age, 13.4 years) with severe and excessive irritability in the context of generalized developmental disorders or ADHD." assertion.
- context label "Adolescents (15-17)" assertion.
- association label "Similarly, De Cos Milas et al. [6] described their clinical experience with paliperidone in adolescents. They presented 3 males and 2 females, age between 15 and 17 years. Diagnoses were autism, borderline personality disorder, schizotypal personality disorder, personality disorder not otherwise specified, and schizophrenia. Prescribed dose was 3–9 mg/day, and actual mean time of treatment duration is 5.8 months. In 4 cases, paliperidone was initiated as a change from other antipsychotic. There were no adverse effects that required discontinuation and in all cases symptoms improved." assertion.
- context label "Children and adolescents" assertion.
- association label "There are no FDA or manufacturer guidelines for use of clozapine in pediatric population. Clozapine has been used in the treatment of refractory schizophrenia in child and adolescents. It is estimated that 40%–50% of patients with very early-onset schizophrenia (VEOS) are nonresponders to first-line neuroleptics and that clozapine is likely to be beneficial." assertion.
- context label "Children and adolescents" assertion.
- association label "Clozapine has a more significant impact for the treatment of positive psychotic symptoms as compared to negative symptoms and has been shown to be effective for aggression, suicidal behaviors, obsessive–compulsive disorder, and autism spectrum disorder." assertion.
- context label "Children and adolescents" assertion.
- association label "Clozapine has a more significant impact for the treatment of positive psychotic symptoms as compared to negative symptoms and has been shown to be effective for aggression, suicidal behaviors, obsessive–compulsive disorder, and autism spectrum disorder." assertion.
- context label "Adults" assertion.
- association label "First-generation antipsychotics (FGA) use was more than that of second-generation antipsychotics (SGA) use in patients with anxiety disorder through the 9-year period. Sulpiride and flupentixol were the two most common FGA in the treatment of anxiety disorder. Patients with specific anxiety disorder (post-traumatic stress disorder, panic disorder/agoraphobia, generalized anxiety disorder, and obsessive-compulsive disorder), female sex, younger age (age < 65 years), comorbidity with major depression or minor depression, antidepressants concurrent use, and visits to psychiatrists, medical centers and primary care were significantly more likely to take prescribed antipsychotics." assertion.
- context label "Adults" assertion.
- association label "First-generation antipsychotics (FGA) use was more than that of second-generation antipsychotics (SGA) use in patients with anxiety disorder through the 9-year period. Sulpiride and flupentixol were the two most common FGA in the treatment of anxiety disorder. Patients with specific anxiety disorder (post-traumatic stress disorder, panic disorder/agoraphobia, generalized anxiety disorder, and obsessive-compulsive disorder), female sex, younger age (age < 65 years), comorbidity with major depression or minor depression, antidepressants concurrent use, and visits to psychiatrists, medical centers and primary care were significantly more likely to take prescribed antipsychotics" assertion.
- DB00875 label "Flupentixol" assertion.
- context label "Adults" assertion.
- association label "First, we estimated the change in the percentage of prescriptions for overall antipsychotics, FGA, and SGA for anxiety disorder visits from 2005 to 2013. We calculated the annual antipsychotic prescription rates as the total number of antipsychotic prescriptions divided by the total number of eligible patients with anxiety visits. The same patients are counted several times if they have several visits.We then stratified this 9-year dataset into three equal parts (2005–2007, 2008–2010, and 2011–2013) and examined the time trends in antipsychotic treatments during anxiety visits. We transformed the calendar years by subtracting 2005 from the year and dividing the results by 8. Thus, the transformed values were 0 for 2005 and 1 for 2013. The odds ratios associated with this transformed variable represent change in the odds of visits in which antipsychotic medication was prescribed across the entire study period (2005–2013). For example, an odds ratio of 2.0 denotes twice the odds that a visit included an antipsychotic at the end (2013) as compared with the start (2005) of the study period. Adjusted odds ratios (aOR) were calculated from the multivariate logistic model with adjustment for age and sex. We repeated similar analysis to examine the trends in the use of selective FGA (i.e., flupenxiol and sulpiride) and individual SGA (i.e., clozapine, risperidone, olanzapine, quetiapine, aripiprazole, and ziprasidone). (...) First-generation antipsychotics (FGA) use was more than that of second-generation antipsychotics (SGA) use in patients with anxiety disorder through the 9-year period. Sulpiride and flupentixol were the two most common FGA in the treatment of anxiety disorder. Patients with specific anxiety disorder (post-traumatic stress disorder, panic disorder/agoraphobia, generalized anxiety disorder, and obsessive-compulsive disorder), female sex, younger age (age < 65 years), comorbidity with major depression or minor depression, antidepressants concurrent use, and visits to psychiatrists, medical centers and primary care were significantly more likely to take prescribed antipsychotics" assertion.
- context label "Adults" assertion.
- association label "First, we estimated the change in the percentage of prescriptions for overall antipsychotics, FGA, and SGA for anxiety disorder visits from 2005 to 2013. We calculated the annual antipsychotic prescription rates as the total number of antipsychotic prescriptions divided by the total number of eligible patients with anxiety visits. The same patients are counted several times if they have several visits.We then stratified this 9-year dataset into three equal parts (2005–2007, 2008–2010, and 2011–2013) and examined the time trends in antipsychotic treatments during anxiety visits. We transformed the calendar years by subtracting 2005 from the year and dividing the results by 8. Thus, the transformed values were 0 for 2005 and 1 for 2013. The odds ratios associated with this transformed variable represent change in the odds of visits in which antipsychotic medication was prescribed across the entire study period (2005–2013). For example, an odds ratio of 2.0 denotes twice the odds that a visit included an antipsychotic at the end (2013) as compared with the start (2005) of the study period. Adjusted odds ratios (aOR) were calculated from the multivariate logistic model with adjustment for age and sex. We repeated similar analysis to examine the trends in the use of selective FGA (i.e., flupenxiol and sulpiride) and individual SGA (i.e., clozapine, risperidone, olanzapine, quetiapine, aripiprazole, and ziprasidone). (...) First-generation antipsychotics (FGA) use was more than that of second-generation antipsychotics (SGA) use in patients with anxiety disorder through the 9-year period. Sulpiride and flupentixol were the two most common FGA in the treatment of anxiety disorder. Patients with specific anxiety disorder (post-traumatic stress disorder, panic disorder/agoraphobia, generalized anxiety disorder, and obsessive-compulsive disorder), female sex, younger age (age < 65 years), comorbidity with major depression or minor depression, antidepressants concurrent use, and visits to psychiatrists, medical centers and primary care were significantly more likely to take prescribed antipsychotics" assertion.
- context label "Adults" assertion.
- association label "First, we estimated the change in the percentage of prescriptions for overall antipsychotics, FGA, and SGA for anxiety disorder visits from 2005 to 2013. We calculated the annual antipsychotic prescription rates as the total number of antipsychotic prescriptions divided by the total number of eligible patients with anxiety visits. The same patients are counted several times if they have several visits.We then stratified this 9-year dataset into three equal parts (2005–2007, 2008–2010, and 2011–2013) and examined the time trends in antipsychotic treatments during anxiety visits. We transformed the calendar years by subtracting 2005 from the year and dividing the results by 8. Thus, the transformed values were 0 for 2005 and 1 for 2013. The odds ratios associated with this transformed variable represent change in the odds of visits in which antipsychotic medication was prescribed across the entire study period (2005–2013). For example, an odds ratio of 2.0 denotes twice the odds that a visit included an antipsychotic at the end (2013) as compared with the start (2005) of the study period. Adjusted odds ratios (aOR) were calculated from the multivariate logistic model with adjustment for age and sex. We repeated similar analysis to examine the trends in the use of selective FGA (i.e., flupenxiol and sulpiride) and individual SGA (i.e., clozapine, risperidone, olanzapine, quetiapine, aripiprazole, and ziprasidone). (...) First-generation antipsychotics (FGA) use was more than that of second-generation antipsychotics (SGA) use in patients with anxiety disorder through the 9-year period. Sulpiride and flupentixol were the two most common FGA in the treatment of anxiety disorder. Patients with specific anxiety disorder (post-traumatic stress disorder, panic disorder/agoraphobia, generalized anxiety disorder, and obsessive-compulsive disorder), female sex, younger age (age < 65 years), comorbidity with major depression or minor depression, antidepressants concurrent use, and visits to psychiatrists, medical centers and primary care were significantly more likely to take prescribed antipsychotics" assertion.
- context label "Adults" assertion.
- association label "First, we estimated the change in the percentage of prescriptions for overall antipsychotics, FGA, and SGA for anxiety disorder visits from 2005 to 2013. We calculated the annual antipsychotic prescription rates as the total number of antipsychotic prescriptions divided by the total number of eligible patients with anxiety visits. The same patients are counted several times if they have several visits.We then stratified this 9-year dataset into three equal parts (2005–2007, 2008–2010, and 2011–2013) and examined the time trends in antipsychotic treatments during anxiety visits. We transformed the calendar years by subtracting 2005 from the year and dividing the results by 8. Thus, the transformed values were 0 for 2005 and 1 for 2013. The odds ratios associated with this transformed variable represent change in the odds of visits in which antipsychotic medication was prescribed across the entire study period (2005–2013). For example, an odds ratio of 2.0 denotes twice the odds that a visit included an antipsychotic at the end (2013) as compared with the start (2005) of the study period. Adjusted odds ratios (aOR) were calculated from the multivariate logistic model with adjustment for age and sex. We repeated similar analysis to examine the trends in the use of selective FGA (i.e., flupenxiol and sulpiride) and individual SGA (i.e., clozapine, risperidone, olanzapine, quetiapine, aripiprazole, and ziprasidone). (...) First-generation antipsychotics (FGA) use was more than that of second-generation antipsychotics (SGA) use in patients with anxiety disorder through the 9-year period. Sulpiride and flupentixol were the two most common FGA in the treatment of anxiety disorder. Patients with specific anxiety disorder (post-traumatic stress disorder, panic disorder/agoraphobia, generalized anxiety disorder, and obsessive-compulsive disorder), female sex, younger age (age < 65 years), comorbidity with major depression or minor depression, antidepressants concurrent use, and visits to psychiatrists, medical centers and primary care were significantly more likely to take prescribed antipsychotics" assertion.
- context label "Adults" assertion.
- association label "Lamotrigine has been long used as an anti-epileptic, mood stabilizer, to treat bipolar disorder in adults and off label as an antidepressant." assertion.
- context label "Adults" assertion.
- association label "This paper seeks to explain the ethical, regulatory and procedural framework for the off-label use of ketamine for treatment-resistant depression within a public healthcare system." assertion.
- context label "Adults" assertion.
- association label "Off-label and novel treatments continue to be considered for more refractory and disabling cases of PTSD." assertion.
- context label "Adults" assertion.
- association label "Only a few pharmacological treatments are available for treating alcohol use disorders (AUDs). Disulfiram, naltrexone and acamprosate are Food and Drug Administration (FDA)-approved and nalmefene is EMA-approved in European Union. Off-label medications, such as baclofen, gabapentin, ondansetron and topiramate are medications commonly prescribed for the treatment of AUD." assertion.
- context label "Adults" assertion.
- association label "Only a few pharmacological treatments are available for treating alcohol use disorders (AUDs). Disulfiram, naltrexone and acamprosate are Food and Drug Administration (FDA)-approved and nalmefene is EMA-approved in European Union. Off-label medications, such as baclofen, gabapentin, ondansetron and topiramate are medications commonly prescribed for the treatment of AUD." assertion.
- context label "Adults" assertion.
- association label "The nicotinic-acetylcholine receptor (nAchR)- antagonist mecamylanine has been found to reduce the stimulus produced by ethanol in human lab studies. The nAchR-antagonist varenicline has also displayed positive effect in reducing alcohol consumption in multiple clinical trials. In this 12- week double-blind trial, participants (n 1⁄4 126) were randomized to either mecamylamine (10 mg daily) or placebo. No medication effect was found for reducing heavy drinking days (HDD) or alcohol craving. Smoking status had no effect on the results. The authors suggest that broad-spectrum nAchR-antagonists may not be beneficial in treat- ing AUD" assertion.
- DB00657 label "Mecamylamine" assertion.
- context label "Adults" assertion.
- association label "In a study published by Wilcox et al. [19], the alpha- 1 adrenergic receptor antagonist prazosin did not differ from placebo in reducing alcohol consump- tion in 36 participants." assertion.
- context label "Adults" assertion.
- association label "These findings suggest that if ketamine is to find a place as an off-label treatment for depression and suicidality in mainstream psychiatry, researchers should study the safety, efficacy, and optimization of oral ketamine. Intravenous and intranasal routes may be monetarily more promising, but the oral route could be of greatest service." assertion.
- context label "Adults" assertion.
- association label "Currently, there are no FDA-approved pharmacotherapies available for CUD, though a number (eg, cannabinoids, antidepressants, anxiolytics, and glutamatergic modulators) have been proposed for off-label use. We identified 12 trials examining psychopharmacological interventions for the treatment of cannabis use disorder. Trials examined antidepressants (ie, escitalopram, fluoxetine, bupropion, nefazodone, venlafaxine, vilazodone), antipsychotics (ie, clozapine, ziprasidone), buspirone, mood stabilizers (ie, divalproex, lithium), and atomoxetine. Overall, studies found that antidepressants as a class were less effective than placebo for the achievement of abstinence (moderate SOE). There was no difference between antidepressants (moderate SOE) or buspirone (low SOE) and placebo in reducing overall cannabis use or retention in treatment. We found low strength evidence of no difference from placebo for antidepressants or buspirone on harms. Antidepressant medications did not impact secondary outcomes (low SOE). Findings for all other psychopharmacotherapies and drug/outcome combinations were either insufficient or were not identified in the current literature." assertion.
- context label "Adults" assertion.
- association label "Currently, there are no FDA-approved pharmacotherapies available for CUD, though a number (eg, cannabinoids, antidepressants, anxiolytics, and glutamatergic modulators) have been proposed for off-label use. We identified 12 trials examining psychopharmacological interventions for the treatment of cannabis use disorder. Trials examined antidepressants (ie, escitalopram, fluoxetine, bupropion, nefazodone, venlafaxine, vilazodone), antipsychotics (ie, clozapine, ziprasidone), buspirone, mood stabilizers (ie, divalproex, lithium), and atomoxetine. Overall, studies found that antidepressants as a class were less effective than placebo for the achievement of abstinence (moderate SOE). There was no difference between antidepressants (moderate SOE) or buspirone (low SOE) and placebo in reducing overall cannabis use or retention in treatment. We found low strength evidence of no difference from placebo for antidepressants or buspirone on harms. Antidepressant medications did not impact secondary outcomes (low SOE). Findings for all other psychopharmacotherapies and drug/outcome combinations were either insufficient or were not identified in the current literature." assertion.
- context label "Adults" assertion.
- association label "Currently, there are no FDA-approved pharmacotherapies available for CUD, though a number (eg, cannabinoids, antidepressants, anxiolytics, and glutamatergic modulators) have been proposed for off-label use. We identified 12 trials examining psychopharmacological interventions for the treatment of cannabis use disorder. Trials examined antidepressants (ie, escitalopram, fluoxetine, bupropion, nefazodone, venlafaxine, vilazodone), antipsychotics (ie, clozapine, ziprasidone), buspirone, mood stabilizers (ie, divalproex, lithium), and atomoxetine. Overall, studies found that antidepressants as a class were less effective than placebo for the achievement of abstinence (moderate SOE). There was no difference between antidepressants (moderate SOE) or buspirone (low SOE) and placebo in reducing overall cannabis use or retention in treatment. We found low strength evidence of no difference from placebo for antidepressants or buspirone on harms. Antidepressant medications did not impact secondary outcomes (low SOE). Findings for all other psychopharmacotherapies and drug/outcome combinations were either insufficient or were not identified in the current literature." assertion.
- context label "Adults" assertion.
- association label "Currently, there are no FDA-approved pharmacotherapies available for CUD, though a number (eg, cannabinoids, antidepressants, anxiolytics, and glutamatergic modulators) have been proposed for off-label use. We identified 12 trials examining psychopharmacological interventions for the treatment of cannabis use disorder. Trials examined antidepressants (ie, escitalopram, fluoxetine, bupropion, nefazodone, venlafaxine, vilazodone), antipsychotics (ie, clozapine, ziprasidone), buspirone, mood stabilizers (ie, divalproex, lithium), and atomoxetine. Overall, studies found that antidepressants as a class were less effective than placebo for the achievement of abstinence (moderate SOE). There was no difference between antidepressants (moderate SOE) or buspirone (low SOE) and placebo in reducing overall cannabis use or retention in treatment. We found low strength evidence of no difference from placebo for antidepressants or buspirone on harms. Antidepressant medications did not impact secondary outcomes (low SOE). Findings for all other psychopharmacotherapies and drug/outcome combinations were either insufficient or were not identified in the current literature." assertion.
- DB06684 label "Vilazodone" assertion.
- context label "Adults" assertion.
- association label "Currently, there are no FDA-approved pharmacotherapies available for CUD, though a number (eg, cannabinoids, antidepressants, anxiolytics, and glutamatergic modulators) have been proposed for off-label use. We identified 12 trials examining psychopharmacological interventions for the treatment of cannabis use disorder. Trials examined antidepressants (ie, escitalopram, fluoxetine, bupropion, nefazodone, venlafaxine, vilazodone), antipsychotics (ie, clozapine, ziprasidone), buspirone, mood stabilizers (ie, divalproex, lithium), and atomoxetine. Overall, studies found that antidepressants as a class were less effective than placebo for the achievement of abstinence (moderate SOE). There was no difference between antidepressants (moderate SOE) or buspirone (low SOE) and placebo in reducing overall cannabis use or retention in treatment. We found low strength evidence of no difference from placebo for antidepressants or buspirone on harms. Antidepressant medications did not impact secondary outcomes (low SOE). Findings for all other psychopharmacotherapies and drug/outcome combinations were either insufficient or were not identified in the current literature." assertion.
- context label "Adults" assertion.
- association label "Currently, there are no FDA-approved pharmacotherapies available for CUD, though a number (eg, cannabinoids, antidepressants, anxiolytics, and glutamatergic modulators) have been proposed for off-label use. We identified 12 trials examining psychopharmacological interventions for the treatment of cannabis use disorder. Trials examined antidepressants (ie, escitalopram, fluoxetine, bupropion, nefazodone, venlafaxine, vilazodone), antipsychotics (ie, clozapine, ziprasidone), buspirone, mood stabilizers (ie, divalproex, lithium), and atomoxetine. Overall, studies found that antidepressants as a class were less effective than placebo for the achievement of abstinence (moderate SOE). There was no difference between antidepressants (moderate SOE) or buspirone (low SOE) and placebo in reducing overall cannabis use or retention in treatment. We found low strength evidence of no difference from placebo for antidepressants or buspirone on harms. Antidepressant medications did not impact secondary outcomes (low SOE). Findings for all other psychopharmacotherapies and drug/outcome combinations were either insufficient or were not identified in the current literature." assertion.
- context label "Adults" assertion.
- association label "Currently, there are no FDA-approved pharmacotherapies available for CUD, though a number (eg, cannabinoids, antidepressants, anxiolytics, and glutamatergic modulators) have been proposed for off-label use. We identified 12 trials examining psychopharmacological interventions for the treatment of cannabis use disorder. Trials examined antidepressants (ie, escitalopram, fluoxetine, bupropion, nefazodone, venlafaxine, vilazodone), antipsychotics (ie, clozapine, ziprasidone), buspirone, mood stabilizers (ie, divalproex, lithium), and atomoxetine. Overall, studies found that antidepressants as a class were less effective than placebo for the achievement of abstinence (moderate SOE). There was no difference between antidepressants (moderate SOE) or buspirone (low SOE) and placebo in reducing overall cannabis use or retention in treatment. We found low strength evidence of no difference from placebo for antidepressants or buspirone on harms. Antidepressant medications did not impact secondary outcomes (low SOE). Findings for all other psychopharmacotherapies and drug/outcome combinations were either insufficient or were not identified in the current literature." assertion.
- context label "Adults" assertion.
- association label "Currently, there are no FDA-approved pharmacotherapies available for CUD, though a number (eg, cannabinoids, antidepressants, anxiolytics, and glutamatergic modulators) have been proposed for off-label use. We identified 12 trials examining psychopharmacological interventions for the treatment of cannabis use disorder. Trials examined antidepressants (ie, escitalopram, fluoxetine, bupropion, nefazodone, venlafaxine, vilazodone), antipsychotics (ie, clozapine, ziprasidone), buspirone, mood stabilizers (ie, divalproex, lithium), and atomoxetine. Overall, studies found that antidepressants as a class were less effective than placebo for the achievement of abstinence (moderate SOE). There was no difference between antidepressants (moderate SOE) or buspirone (low SOE) and placebo in reducing overall cannabis use or retention in treatment. We found low strength evidence of no difference from placebo for antidepressants or buspirone on harms. Antidepressant medications did not impact secondary outcomes (low SOE). Findings for all other psychopharmacotherapies and drug/outcome combinations were either insufficient or were not identified in the current literature." assertion.
- context label "Adults" assertion.
- association label "Psychosis is broadly defined as a disengagement from reality. It describes syndromes that impair both thought content and thought process. Psychosis negatively impacts an individual's quality of life, in addition to the families caring for them. Psychosis with different types of hallucinations and delusions occurs in the context of delirium. Neuropsychiatric symptoms (NPS) are almost universal in the course of common neurodegenerative disorders (NDD) like Alzheimer's disease (AD) or Parkinson's disease (PD). In this paper, the authors took an effort to characterize AD and PD psychosis with a special focus on the most diagnostically reliable features. Quetiapine (see supplement) is also commonly used in (off-label) for NPS in AD." assertion.
- context label "Adults" assertion.
- association label "Clinical trial data for mood disorders as well as other psychiatric disorders, including borderline personality disorder, schizophrenia, posttraumatic stress disorder (PTSD), obsessive-compulsive disorder, and panic disorder, will be discussed" assertion.
- context label "Adults" assertion.
- association label "Clinical trial data for mood disorders as well as other psychiatric disorders, including borderline personality disorder, schizophrenia, posttraumatic stress disorder (PTSD), obsessive-compulsive disorder, and panic disorder, will be discussed" assertion.
- context label "Adults" assertion.
- association label "Clinical trial data for mood disorders as well as other psychiatric disorders, including borderline personality disorder, schizophrenia, posttraumatic stress disorder (PTSD), obsessive-compulsive disorder, and panic disorder, will be discussed" assertion.
- context label "Adults" assertion.
- association label "Clinical trial data for mood disorders as well as other psychiatric disorders, including borderline personality disorder, schizophrenia, posttraumatic stress disorder (PTSD), obsessive-compulsive disorder, and panic disorder, will be discussed" assertion.
- context label "Adults" assertion.
- association label "Patients with Parkinson's disease psychosis (PDP) are often treated with an atypical antipsychotic, especially quetiapine or clozapine, but side effects, lack of sufficient efficacy, or both may motivate a switch to pimavanserin, the first medication approved for management of PDP." assertion.
- context label "Adults" assertion.
- association label "Off-label use of ketamine for mood disorders is proving popular in the United States. Meanwhile, preclinical data suggests that (R)-ketamine can exert longer-lasting antidepressant effects than (S)-ketamine in animal models of depression, and (R)-ketamine may have less detrimental side effects than (R,S)-ketamine and (S)-ketamine." assertion.
- context label "Adults" assertion.
- association label "Clinician's annotation: “Insomnia—c/w trazodone at night”" assertion.
- context label "Adults" assertion.
- association label "Clinician's annotation: “Depression: stable: continue Paxil and trazodone for sleep”" assertion.
- context label "Adults" assertion.
- association label "Clinician's annotation: “history of migraines and depression, both well controlled on bupropion and amitriptyline”" assertion.
- context label "Adults" assertion.
- association label "Clinician's annotation: “Will try an antidepressant to see if it helps to improve interest in activities. The history is suggestive of depression”" assertion.
- context label "Adults" assertion.
- association label "Clinician's annotation: “foot pain—chronic, not neuropathy apparently, will give trial of nortrip in case”" assertion.
- context label "Adults" assertion.
- association label "Clinician's annotation: “Back pain improved with addition of nortriptyline”" assertion.
- context label "Adults" assertion.
- association label "Clinician's annotation: “Has been taking increased dose of nortriptyline since last visit and notes much less pain radiating to leg”" assertion.